ArticleCardiology research2026
Pristine+™ Everolimus-Eluting Cobalt-Chromium Coronary Stent System: A Prospective, Multicenter Registry.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent advances in percutaneous coronary interventions (PCIs) have substantially improved clinical outcomes. Generating real-world evidence on the 1-year outcomes of ultrathin-strut drug-eluting stents (DES) remains important, particularly in healthcare settings where cost and accessibility may influence stent selection. Methods: A prospective, single-arm, multicenter registry was conducted to evaluate the 1-year safety and efficacy of an indigenous everolimus-eluting cobalt-chromium stent (EES) (Pristine+™ - Make: Relisys Medical Devices Limited, India) featuring an ultrathin strut (60-µm) design. The primary endpoint was the 1-year incidence of major adverse cardiac event (MACE) defined as a composite of cardiac death (CD), myocardial infarction (MI), and stent thrombosis (ST). Results: The study enrolled 1,088 patients, predominantly male (78.9%). High prevalence of diabetes mellitus (34.7%), hypertension (63.9%), and smoking history (25.7%) was noted. The mean age was 58.6 ± 10.6 years, with 69.9% between 36 and 65 years. A total of 95.9% completed the 1-year follow-up. At 1-year, the Kaplan-Meier incidence of MACE was 2.89% (40 events), comprising 18 CD (1.65%), 13 MI (1.19%), and nine ST (0.83%). All-cause mortality was 2.3% (25 events). One target-vessel myocardial infarction (TV-MI; 0.09%) was reported and no clinically indicated target-lesion revascularization (CI-TLR) events occurred. Conclusion: This study demonstrated favorable 1-year clinical outcomes with Pristine+™, reflected by low rates of MACE and no CI-TLR during the 1-year follow-up. A total of 1,386 Pristine+ EES were implanted in this study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.